Publications by authors named "Nicole L Drezner"

2 Publications

  • Page 1 of 1

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

J Thorac Oncol 2018 Dec 27;13(12):1818-1831. Epub 2018 Sep 27.

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes. There are unique opportunities and challenges with the neoadjuvant approach to drug development. To achieve more rapid knowledge turns, study designs, endpoints, and definitions of pathologic response should be standardized and harmonized. Continued dialogue with all stakeholders will be critical to design and test novel induction strategies, which could expedite drug development for patients with early lung cancer who are at high risk for metastatic recurrence.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
December 2018

The impact of molecular analysis on the survival of children with embryonal tumors.

Transl Pediatr 2016 Jan;5(1):5-8

Brain Tumor Institute, Children's National Health System, Children's National Medical Center, Washington, DC, USA.

Embryonal tumors represent a heterogeneous group of malignancies characterized by poorly differentiated cells and generally aggressive behavior. Although advances in survival rates have been made in several of these tumor types, including Wilms' tumor, retinoblastoma, and medulloblastoma, survival of patients with central nervous system (CNS) embryonal tumors, including primitive neuro-ectodermal tumors (PNETs) and atypical teratoid rhabdoid tumors (AT/RT), are particularly poor. Advancing molecular analysis techniques and the development of gene expression profiles has led to the formulation of different subdivisions within many of the umbrella CNS tumor groups with clinical and prognostic implications. Some subgroups have been identified as having improved survivorships, likely not captured by large scale population data given their small numbers and relatively recent characterization. Importantly, identification of differing molecular pathways has begun to result in targeted therapies which may pave the way for even more surviving patients in the coming years.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
January 2016